RenovoRx Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • RenovoRx's estimated annual revenue is currently $4.5M per year.(i)
  • RenovoRx's estimated revenue per employee is $251,000

Employee Data

  • RenovoRx has 18 Employees.(i)
  • RenovoRx grew their employee count by -31% last year.

RenovoRx's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
CEOReveal Email/Phone
3
SVP Clinical OperationsReveal Email/Phone
4
SVP Clinical OperationsReveal Email/Phone
5
VP & ControllerReveal Email/Phone
6
SVP Clinical OperationsReveal Email/Phone
7
Sr. Director Clinical Research and OperationsReveal Email/Phone
8
Chief Medical Officer, FounderReveal Email/Phone
9
Chief Financial OfficerReveal Email/Phone
10
Director ImagingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is RenovoRx?

RenovoRx is a medical device company headquartered in Silicon Valley, California. We are developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. The ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of our technology. We have received FDA clearance for the RenovoCathâ„¢ RC120 and are now introducing our innovative technology to the clinical market. RenovoRx is a highly motivated team with broad experience and an exciting vision for the future of targeted delivery. We are backed by a Broad Medical Advisory board and a strong Board of Directors. Please contact us at info@renovorx.com to learn more.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$4.5M

Revenue (est)

-31%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RenovoRx News

2022-04-20 - RenovoRx Sponsors Pancreatic Cancer Action Network's ...

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors...

2022-04-17 - RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 85.0% in ...

Citadel Advisors LLC bought a new position in shares of RenovoRx during the 3rd quarter valued at about $73,000. Two Sigma Securities LLC bought...

2022-03-30 - RenovoRx Reports Full Year 2021 Financial Results

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M18-40%N/A
#2
$2.4M18-33%N/A
#3
$1.4M18-18%N/A
#4
$1.4M18-10%$406.5M
#5
$1.4M18-33%$173M